UnknownPhase 2NCT00003681
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Studying Acquired idiopathic sideroblastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Principal Investigator
- Roel Willemze, MD, PhDLeiden University Medical Center
- Intervention
- epoetin alfa(biological)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 1998
Study locations (12)
- Universitaetsklinik, Innsbruck, Austria
- Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
- A.Z. St. Jan, Bruges, Belgium
- Institut Jules Bordet, Brussels (Bruxelles), Belgium
- Universitair Ziekenhuis Antwerpen, Edegem, Belgium
- University Hospital - Olomouc, Olomouc, Czechia
- Institute of Hematology and Blood Transfusion, Prague, Czechia
- Onkologicka Klinka A Onkologicka Lab, Prague (Praha), Czechia
- Leiden University Medical Center, Leiden, Netherlands
- Hospital Escolar San Joao, Porto, Portugal
- Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
- University Hospital, Basel, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003681 on ClinicalTrials.govOther trials for Acquired idiopathic sideroblastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06270771OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot StudySunnybrook Health Sciences Centre
- RECRUITINGNANCT04869683Biocollection in MyeloDysplastic Syndrome (P-MDS)University Hospital, Brest
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT00392353Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaNational Cancer Institute (NCI)
See all trials for Acquired idiopathic sideroblastic anemia →